Redhill Biopharma (RDHL) Competitors $2.10 +0.04 (+1.94%) Closing price 07/8/2025 03:59 PM EasternExtended Trading$2.09 -0.01 (-0.48%) As of 07/8/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDHL vs. CARM, MRKR, CTXR, RVPH, PMN, GOVX, PRPH, ALLR, HOTH, and LEXXShould you be buying Redhill Biopharma stock or one of its competitors? The main competitors of Redhill Biopharma include Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), Promis Neurosciences (PMN), GeoVax Labs (GOVX), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), Hoth Therapeutics (HOTH), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Redhill Biopharma vs. Its Competitors Carisma Therapeutics Marker Therapeutics Citius Pharmaceuticals Reviva Pharmaceuticals Promis Neurosciences GeoVax Labs ProPhase Labs Allarity Therapeutics Hoth Therapeutics Lexaria Bioscience Carisma Therapeutics (NASDAQ:CARM) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends. Do analysts recommend CARM or RDHL? Carisma Therapeutics presently has a consensus target price of $1.93, indicating a potential upside of 378.86%. Given Carisma Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Carisma Therapeutics is more favorable than Redhill Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Redhill Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in CARM or RDHL? 44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are owned by institutional investors. 12.6% of Carisma Therapeutics shares are owned by insiders. Comparatively, 6.8% of Redhill Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is CARM or RDHL more profitable? Redhill Biopharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% Redhill Biopharma N/A N/A N/A Which has more volatility and risk, CARM or RDHL? Carisma Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Redhill Biopharma has a beta of 4.22, indicating that its stock price is 322% more volatile than the S&P 500. Does the media refer more to CARM or RDHL? In the previous week, Carisma Therapeutics had 3 more articles in the media than Redhill Biopharma. MarketBeat recorded 4 mentions for Carisma Therapeutics and 1 mentions for Redhill Biopharma. Carisma Therapeutics' average media sentiment score of 0.22 beat Redhill Biopharma's score of 0.00 indicating that Carisma Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carisma Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Redhill Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, CARM or RDHL? Redhill Biopharma has lower revenue, but higher earnings than Carisma Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.86-$60.48M-$1.56-0.26Redhill Biopharma$8.04M0.60-$8.27MN/AN/A SummaryCarisma Therapeutics beats Redhill Biopharma on 10 of the 14 factors compared between the two stocks. Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedhill BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.73M$2.44B$5.47B$8.95BDividend YieldN/A1.80%5.25%4.04%P/E RatioN/A8.9826.9920.11Price / Sales0.60724.46428.71119.81Price / CashN/A159.8036.8257.86Price / Book-0.574.517.985.56Net Income-$8.27M$31.26M$3.16B$248.40M7 Day Performance5.00%3.57%2.38%4.67%1 Month Performance2.44%1.28%2.17%6.64%1 Year Performance-99.06%1.08%33.81%21.31% Redhill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedhill BiopharmaN/A$2.10+1.9%N/A-99.0%$4.73M$8.04M0.00210CARMCarisma Therapeutics2.3682 of 5 stars$0.39-2.2%$1.93+391.6%-66.2%$16.74M$19.63M-0.2520MRKRMarker Therapeutics3.797 of 5 stars$1.53+4.8%$13.17+760.6%-65.6%$16.52M$6.59M-1.1560Positive NewsGap UpCTXRCitius Pharmaceuticals2.4148 of 5 stars$1.59+3.9%$53.00+3,233.3%-87.2%$16.27MN/A0.0020News CoverageHigh Trading VolumeRVPHReviva Pharmaceuticals2.2723 of 5 stars$0.38+12.9%$9.00+2,261.6%-69.4%$16.20MN/A-0.485High Trading VolumePMNPromis Neurosciences3.3559 of 5 stars$0.48+0.7%$4.50+830.1%-79.7%$15.70MN/A-9.685Gap UpGOVXGeoVax Labs3.3193 of 5 stars$0.87-9.8%$11.10+1,182.2%-77.4%$15.29M$3.95M-0.2410PRPHProPhase Labs0.768 of 5 stars$0.39+6.6%N/A-87.1%$15.25M$6.77M-0.31130ALLRAllarity Therapeutics0.9645 of 5 stars$1.01+1.0%N/A-83.6%$15.08MN/A0.0010HOTHHoth Therapeutics1.4161 of 5 stars$1.17+3.5%$4.00+241.9%+44.1%$14.93MN/A-1.034LEXXLexaria Bioscience2.8462 of 5 stars$0.87+2.5%$7.00+704.6%-65.9%$14.91M$460K-1.477Upcoming Earnings Related Companies and Tools Related Companies Carisma Therapeutics Competitors Marker Therapeutics Competitors Citius Pharmaceuticals Competitors Reviva Pharmaceuticals Competitors Promis Neurosciences Competitors GeoVax Labs Competitors ProPhase Labs Competitors Allarity Therapeutics Competitors Hoth Therapeutics Competitors Lexaria Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDHL) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
